Kriya Therapeutics secured USD 313.3 Million for new strategic move. The filing showed two backers took part—but didn’t reveal their names.
Kriya an integrated gene therapy company operating out of Palo Alto, California, and Research Triangle Park, North Carolina is focusing on developing single-dose gene therapies to cure ophthalmology, neurology, as well as metabolic diseases. The company’s pipeline products include geographic atrophy, thyroid eye disease, trigeminal neuralgia, focal epilepsy, type 1 diabetes, metabolic dysfunction-associated steatohepatitis (MASH), etc.
Kriya’s pipeline includes:
- KRIYA‑825 (Geographic Atrophy): A suprachoroidal, one-time injection expressing a CR2-CR1 fusion protein to inhibit complement pathways, aiming to slow vision loss in GA patients.
- KRIYA‑825 for Geographic Atrophy (GA), manufactured as a one-time suprachoroidal injection to inhibit complement pathways and potentially slow vision loss.
- Neurology Programs:
- KRIYA‑748 (Trigeminal Neuralgia): Utilizes an engineered ion channel activated by an oral small molecule to modulate nerve excitability.
- KRIYA‑382 (Focal Epilepsy): A similar chemogenetic approach targeting epileptic brain foci
- Metabolic Candidates:
- KRIYA‑839 (Type 1 Diabetes): Intramuscular delivery of insulin and glucokinase genes to promote durable glycemic control.
- KRIYA‑497 (MASH/NASH): AAV-mediated expression of FGF21 to reduce liver fibrosis and improve metabolic outcomes
The company aims to conduct five programs for clinical stages by the end of 2025, this new financing positions Kriya for accelerated translational impact and scale-up across its therapeutic platform.
Multiple investors have contributed in Kriya Therapeutics in previous financing rounds which are Patient Square Capital, Foresite Capital, Bluebird Ventures, Amplo, Woodline Partners, Narya, QVT Financial, CAM Capital, and the T1D Fund, among others.